MediWound Ltd. (NASDAQ:MDWD) Q4 2023 Earnings Conference Call March 21, 2024 8:30 AM ET

Company Participants

Gaia Shamis - LifeSci Advisors
Ofer Gonen - Chief Executive Officer
Barry Wolfenson - Executive Vice President of Strategy & Corporate Development
Hani Luxenburg - Chief Financial Officer

Conference Call Participants

Joshua Jennings - TD Cowen
Francois Brisebois - Oppenheimer
Swayampakula Ramakanth - HC Wainwright
Michael Okunewitch - Maxim Group

Operator

Good day, and welcome to MediWound’s Fourth Quarter and Full Year 2023 Earnings Call. [Operator Instructions].

At this time, I would like to turn the conference over to Gaia Shamis of LifeSci Advisors. Please go ahead.

Gaia Shamis

Thank you, operator, and welcome, everyone. Today, before the market opened, MediWound issued a press release announcing financial results for the fourth quarter and full year ended December 31, 2023. You may access that release on the company's website under the Investors tab.

With us today are Ofer Gonen, Chief Executive Officer of MediWound; Hani Luxenburg, Chief Financial Officer; and Barry Wolfenson, Executive Vice President of Strategy and Corporate Development. Following our prepared remarks, we will open the call for Q&A.

Before we begin, I would like to remind everyone that statements made during this call, including the Q&A session, relating to MediWound's expected future performance, future business prospects or future events or plans are forward-looking statements as defined under the Private Securities Litigation Reform Act of 1995. Although the company believes that the expectations reflected in such forward-looking statements are based upon reasonable assumptions, actual outcomes and results are subject to risks and uncertainties and could differ materially from those forecast due to the impact of many factors beyond the control of MediWound.

The company assumes no obligation to update or supplement any forward-looking statements whether as a result of new information, future events or otherwise. Participants are directed to the cautionary notes set forth in today's press release as well as the risk factors set forth in MediWound's annual report filed with the SEC for factors that could cause actual results to differ materially from those anticipated in the forward-looking statements. The conference call is the property of MediWound and any recording or rebroadcast is expressly prohibited without the written consent of MediWound.

Now I would like to turn the call over to Ofer Gonen, Chief Executive Officer of MediWound. Ofer?

Ofer Gonen

Thank you, Gaia, and good morning, everyone. Welcome to MediWound's fourth quarter and full year 2023 conference call. Joining me today are Hani Luxenburg, our Chief Financial Officer, and Barry Wolfenson, our Executive Vice President of Strategy & Corporate Development. Following our discussion of the financial results and business highlights, we will open the call for questions.